Syndax Pharmaceuticals, Inc. (SNDX)
9.54
+0.17
(+1.81%)
USD |
NASDAQ |
Nov 06, 16:00
9.79
+0.25
(+2.62%)
After-Hours: 20:00
Syndax Pharmaceuticals Profit Margin (Quarterly) : -59.34% for Sept. 30, 2026
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -59.34% |
| June 30, 2026 | -67.82% |
| March 31, 2026 | -65.79% |
| December 31, 2025 | -98.96% |
| September 30, 2025 | -132.4% |
| June 30, 2025 | -189.3% |
| March 31, 2025 | -423.3% |
| December 31, 2024 | -1.23K% |
| September 30, 2024 | -673.0% |
| June 30, 2024 | -1.94K% |
| March 31, 2024 | |
| December 31, 2023 | |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | 76.00% |
| September 30, 2021 | -166.8% |
| June 30, 2021 | -6.04K% |
| Date | Value |
|---|---|
| March 31, 2021 | -7.31K% |
| December 31, 2020 | -5.37K% |
| September 30, 2020 | -5.39K% |
| June 30, 2020 | -4.50K% |
| March 31, 2020 | -5.05K% |
| December 31, 2019 | -3.68K% |
| September 30, 2019 | -3.38K% |
| June 30, 2019 | -3.94K% |
| March 31, 2019 | -3.77K% |
| December 31, 2018 | -4.96K% |
| September 30, 2018 | -4.57K% |
| June 30, 2018 | -4.85K% |
| March 31, 2018 | -5.12K% |
| December 31, 2017 | -1.60K% |
| September 30, 2017 | -4.95K% |
| June 30, 2017 | -4.47K% |
| March 31, 2017 | -4.25K% |
| December 31, 2016 | -3.55K% |
| September 30, 2016 | -4.91K% |
| June 30, 2016 | -2.74K% |
| March 31, 2016 | -3.39K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 15.64% |
| Emergent BioSolutions, Inc. | -29.73% |
| Incyte Corp. | -50.40% |
| Vertex Pharmaceuticals, Inc. | 19.01% |
| Travere Therapeutics, Inc. | -27.18% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -477.0% |
| Return on Assets | -35.50% |
| Return on Invested Capital | -43.02% |
| Gross Profit Margin (Quarterly) | 83.19% |
| Operating Margin (Quarterly) | -50.30% |
| Return on Net Operating Assets | -208.4% |